Alzheon Alzheimer’s Asset Poised for Phase III with High Hopes
Synopsis : Alzheon today posted positive results from its Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders…
Synopsis : Alzheon today posted positive results from its Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders…